What is SHINGRIX?
SHINGRIX is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:
- adults 50 years of age or older;
- adults 18 years of age or older at increased risk of HZ.1,2
SHINGRIX▼ demonstrated >90% efficacy against shingles in all age groups 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.1,2,5,6
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
Date of preparation: July 2021
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2021 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.